📰 Early Access Program News
Page 7 - Early Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Early Access Program. Real-time updates on events, politics, business and more.
November 3, 2023
/PRNewswire/ -- Pierre Fabre Laboratories announced today an expanded global partnership with Atara Biotherapeutics, a leader in T-cell immunotherapy,...
November 2, 2023
LYON, France, November 02, 2023--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced today that extended results from its Early Access Program of MaaT013 in 111 patients (additional 30 patients included in the Program compared to last year) with aGvHD and the design of its Phase 2b study ev...
November 2, 2023
With more investment in AI, computing capacity and skills, Australia’s Microsoft partners look at the opportunities ahead.
November 2, 2023
Poster 1 presents Early Access Program (EAP) data for 111 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.Poster 2 details the Phase 2b randomized, double-blinded study evaluating MaaT033 to enhance overall survival in allogenic hematopoietic cell transplantation patients.For the seventh conse...
October 30, 2023
Biophytis / Key word(s): MiscellaneousBiophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil 30-Oct-2023 / 06:00 CET/CEST Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos...
October 30, 2023
Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement ...
October 30, 2023
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 30,2023 / Biophytis SA (Nasdaq CM:BPTS)(PARIS:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics
October 30, 2023
This week on Cold Take, Frost takes a look at the sad state of consumer protections.
October 23, 2023
(2023-10-23 | NDAQ:MRUS) Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
October 23, 2023
23.10.2023 - - 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients - 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients - Sufficient clinical data expected in 1H24 to support potential BLA submissions UTRECHT, The ... Seite 1